Amgen’s osteoporosis bone-forming drug Evenity (romosozumab) has been approved in Japan, ahead of a crunch review by advisers to the US regulator later this month. Evenity could have been on the ...
Hosted on MSN1mon
Amgen targets $34.3B-$35.7B in 2025 revenues with strong growth in key therapeutic areasAmgen highlighted its robust performance in 2024 ... including approval and launch in Japan. UPLIZNA and TEZSPIRE also demonstrated strong performance and promising growth opportunities in ...
Amgen’s most advanced obesity asset MariTide is entering Maritime—that is, a phase 3 program that includes two freshly launched trials. Historically, the California-based pharma has remained ...
The American Academy of Dermatology (AAD) meeting last week continued to provide positive news, including from US biotech ...
Amgen (NASDAQ:AMGN) has announced the beginning of two Phase 3 studies for its weight loss candidate MariTide as the company aims to take a slice of a burgeoning obesity drug market dominated by ...
Upcoming patent losses are looming large for a number of pharma giants, including Amgen. The company reported a strong 2024, with revenue increasing 19% from the year before to $33.4 billion and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback